Cigna Q1 Earnings Beat Estimates on Strong Evernorth Unit
Cigna reported Q1 2026 earnings that beat analyst estimates, fueled by a 9% revenue jump in its Evernorth pharmacy unit despite rising drug costs. The company also lifted its full-year EPS guidance to at least $30.35.
Key Numbers
Cigna (CI) reported first-quarter 2026 results that surpassed analyst expectations, driven by strong performance from its Evernorth pharmacy benefits unit. Evernorth's revenue grew 9% year-over-year despite higher pharmacy costs, contributing to the earnings beat.
Key Financial Results
| Metric | Q1 2026 | vs. Estimates |
|---|---|---|
| EPS | Beat estimates | Above consensus |
| Evernorth Revenue | +9% YoY | - |
The company did not disclose total revenue or net income in the preliminary report.
Highlights from the Release
Cigna attributed the strong performance to continued growth in Evernorth, which includes pharmacy benefit management and specialty health services. Despite rising drug costs, the unit achieved revenue growth due to increased membership and value-added services.
Future Guidance
Cigna raised its full-year 2026 EPS guidance to at least $30.35, up from previous guidance. This revision reflects confidence in sustained business momentum.
Impact on the Stock
Cigna's stock (CI) is expected to react positively to the earnings beat and guidance raise. Shares rose in early trading following the announcement.
What This Means for Investors
Cigna's report highlights the strength of its Evernorth unit in managing cost pressures, underscoring the resilience of its business model. The guidance raise provides a positive signal on profitability outlook, but investors should monitor pharmacy cost trends and competition in the health insurance sector.
Frequently Asked Questions
Found this useful? Share it